Kodama Susumu, Moore Rick, Yamamoto Yukio, Negishi Masahiko
Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.
Biochem J. 2007 Nov 1;407(3):373-81. doi: 10.1042/BJ20070481.
The nuclear PXR (pregnane X receptor) was originally characterized as a key transcription factor that activated hepatic genes encoding drug-metabolizing enzymes. We have now demonstrated that PXR also represses glucagon-activated transcription of the G6Pase (glucose-6-phosphatase) gene by directly binding to CREB [CRE (cAMP-response element)-binding protein]. Adenoviral-mediated expression of human PXR (hPXR) and its activation by rifampicin strongly repressed cAMP-dependent induction of the endogenous G6Pase gene in Huh7 cells. Using the -259 bp G6Pase promoter construct in cell-based transcription assays, repression by hPXR of PKA (cAMP-dependent protein kinase)-mediated promoter activation was delineated to CRE sites. GST (glutathione transferase) pull-down and immunoprecipitation assays were employed to show that PXR binds directly to CREB, while gel-shift assays were used to demonstrate that this binding prevents CREB interaction with the CRE. These results are consistent with the hypothesis that PXR represses the transcription of the G6Pase gene by inhibiting the DNA-binding ability of CREB. In support of this hypothesis, treatment with the mouse PXR activator PCN (pregnenolone 16alpha-carbonitrile) repressed cAMP-dependent induction of the G6Pase gene in primary hepatocytes prepared from wild-type, but not from PXR-knockout, mice, and also in the liver of fasting wild-type, but not PXR-knockout, mice. Moreover, ChIP (chromatin immunoprecipitation) assays were performed to show a decreased CREB binding to the G6Pase promoter in fasting wild-type mice after PCN treatment. Thus drug activation of PXR can repress the transcriptional activity of CREB, down-regulating gluconeogenesis.
核孕烷X受体(PXR)最初被鉴定为一种关键转录因子,可激活编码药物代谢酶的肝脏基因。我们现已证明,PXR还通过直接结合CREB[CRE(cAMP反应元件)结合蛋白]来抑制胰高血糖素激活的G6Pase(葡萄糖-6-磷酸酶)基因的转录。腺病毒介导的人PXR(hPXR)表达及其被利福平激活,强烈抑制了Huh7细胞中内源性G6Pase基因的cAMP依赖性诱导。在基于细胞的转录分析中使用-259 bp G6Pase启动子构建体,hPXR对PKA(cAMP依赖性蛋白激酶)介导的启动子激活的抑制作用被定位到CRE位点。采用谷胱甘肽转移酶(GST)下拉和免疫沉淀分析表明PXR直接与CREB结合,而凝胶迁移分析则用于证明这种结合可阻止CREB与CRE相互作用。这些结果与以下假设一致:PXR通过抑制CREB的DNA结合能力来抑制G6Pase基因的转录。为支持这一假设,用小鼠PXR激活剂孕烯醇酮16α-腈(PCN)处理,可抑制从野生型而非PXR基因敲除小鼠制备的原代肝细胞中G6Pase基因的cAMP依赖性诱导,也可抑制禁食野生型而非PXR基因敲除小鼠肝脏中该基因的诱导。此外,进行染色质免疫沉淀(ChIP)分析显示,PCN处理后,禁食野生型小鼠中CREB与G6Pase启动子的结合减少。因此,PXR的药物激活可抑制CREB的转录活性,下调糖异生作用。